Home Physical Sciences Crystal structure of 9-methoxy-2,3,4,4a,5,6-hexahydro-1H-pyrido [1′,2′:1,6]pyrazino[2,3-b]quinoxaline, C15H18N4O
Article Open Access

Crystal structure of 9-methoxy-2,3,4,4a,5,6-hexahydro-1H-pyrido [1′,2′:1,6]pyrazino[2,3-b]quinoxaline, C15H18N4O

  • Qiu Yu Zhang ORCID logo and Yu Yu EMAIL logo
Published/Copyright: March 7, 2022
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 237 Issue 3

Abstract

C15H18N4O, triclinic, P 1 ‾ (no. 2), a = 6.7562(5) Å, b = 9.5520(6) Å, c = 11.4227(8) Å, α = 97.206(5)°, β = 102.335(6)°, γ = 108.614(7)°, V = 667.39(9) Å3, Z = 2, R gt (F) = 0.0480, wR ref (F 2) = 0.1388, T = 150 K.

CCDC no.: 2150466

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colorless block
Size: 0.15 × 0.12 × 0.10 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.09 mm−1
Diffractometer, scan mode: SuperNova, ω
θ max, completeness: 25.0°, >99%
N(hkl)measured, N(hkl)unique, R int: 4208, 2346, 0.021
Criterion for I obs, N(hkl)gt: I obs > 2 σ(I obs), 1896
N(param)refined: 182
Programs: CrysAlisPRO [1], Olex2 [2], SHELX [3], WinGX/ORTEP [4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
O1 0.13061 (17) 0.42481 (12) 0.13536 (10) 0.0290 (3)
N1 0.6458 (2) 0.17601 (14) 0.69722 (11) 0.0211 (3)
N2 0.95986 (19) 0.36062 (14) 0.60444 (11) 0.0225 (3)
H2 1.057240 0.413802 0.574076 0.027*
N3 0.3767 (2) 0.19211 (14) 0.53973 (11) 0.0211 (3)
N4 0.69975 (19) 0.38572 (13) 0.45230 (11) 0.0195 (3)
C1 0.4747 (3) 0.05508 (18) 0.72461 (14) 0.0280 (4)
H1A 0.439908 −0.038301 0.666618 0.034*
H1B 0.344944 0.080452 0.714896 0.034*
C2 0.5431 (3) 0.0319 (2) 0.85271 (15) 0.0335 (4)
H2A 0.558185 0.120326 0.910888 0.040*
H2B 0.431362 −0.054031 0.864890 0.040*
C3 0.7540 (3) 0.0050 (2) 0.87684 (16) 0.0350 (4)
H3A 0.735549 −0.089384 0.825127 0.042*
H3B 0.798266 −0.002535 0.961657 0.042*
C4 0.9272 (3) 0.13371 (19) 0.85060 (14) 0.0290 (4)
H4A 1.058172 0.109911 0.858984 0.035*
H4B 0.960553 0.224401 0.911371 0.035*
C5 0.8621 (2) 0.16554 (17) 0.72356 (14) 0.0259 (4)
H5 0.859812 0.082446 0.662865 0.031*
C6 1.0276 (2) 0.30955 (18) 0.71385 (14) 0.0248 (4)
H6A 1.054731 0.387593 0.784598 0.030*
H6B 1.162729 0.293532 0.715075 0.030*
C7 0.7503 (2) 0.32845 (16) 0.54783 (13) 0.0179 (3)
C8 0.5820 (2) 0.22788 (16) 0.59313 (13) 0.0189 (3)
C9 0.3223 (2) 0.25400 (16) 0.44026 (13) 0.0204 (4)
C10 0.1034 (2) 0.22143 (17) 0.38113 (14) 0.0241 (4)
H10 −0.003985 0.158675 0.409732 0.029*
C11 0.0459 (3) 0.28071 (18) 0.28207 (14) 0.0263 (4)
H11 −0.099847 0.259365 0.244387 0.032*
C12 0.2066 (2) 0.37386 (17) 0.23708 (13) 0.0233 (4)
C13 0.4227 (2) 0.40793 (17) 0.29314 (13) 0.0221 (4)
H13 0.528474 0.469533 0.262840 0.027*
C14 0.4832 (2) 0.34936 (16) 0.39633 (13) 0.0188 (4)
C15 0.2883 (3) 0.5066 (2) 0.08046 (15) 0.0333 (4)
H15A 0.217304 0.532332 0.008607 0.050*
H15B 0.368249 0.445502 0.057984 0.050*
H15C 0.385878 0.597305 0.137671 0.050*

Source of material

Piperidin-2-ylmethanamine (1.1 g, 10 mmol), 2,3-dichloro-6-methoxyquinoxaline (2.3 g, 10 mmol) were added into a round bottom flask. K2CO3 (2.7 g, 20 mmol) was added after the solid was dissolved in 20 ml DMF. The mixture was stirred at 110 °C under a nitrogen atmosphere for 6 h. After cooling to room temperature, the reaction mixture was slowly poured into 200 ml purified water and filtered. The filter cake was washed with purified water (50 ml*3) and desiccated at 80 °C for 5 h, then acquired the yellow solid product (yield 61.1%). Crystals were grown by slowly crystallization from methanol. The colorless crystals were obtained by filtration and desiccation.

Experimental details

Single crystal X-ray data was collected on a SuperNova four-circle diffractometer at 149.99 K [1]. Using Olex2, the structure was solved with SHELXT program and refined with the SHELXL refinement package [2, 3]. The crystal structure of title compound was visualized using Ortep3 software [4]. All hydrogen atoms were placed in their geometrically idealized positions.

Comment

Tetrazanbigen (TNBG) is an originally designed and synthesized leading compound bearing the quinoxaline core and showing anticancer activity in vitro and in vivo [5]. Based on SAR, our research team has reported a series of derivatives with improved physical properties and biological effect comparing to TNBG [6], [7], [8]. TNBG was synthesized from (1,2,3,4-tetrahydroisoquinolin-1-yl)methanamine [9] and 2,3-dichloro-6-methoxyquinoxaline [10] and its derivatives were substituted with alkaline side chains leaving basic structure of TNBG unchanged. In this study, in order to diminish molecular weight and structural rigidity, an attempt was carried out to modify the main scaffold of TNBG by deducting a benzene ring [11]. Hence, the title compound was synthesized possessing superior water solubility and equivalent anticancer activity to reported TNBG derivatives.

In conclusion, we report the synthesis and crystal structure of the title compound which is a pivotal antitumor intermediate for further derivation. There is one molecule in the asymmetric unit of the title structure (see the Figure). All bond lengths and angles are in the expected ranges [12, 13].

Corresponding author: Yu Yu, School of Pharmacy, Chongqing Medical University, Chongqing 400016, P. R. China, E-mail:

Funding source: National Natural Science Foundation of China

Award Identifier / Grant number: 30772595

Award Identifier / Grant number: 30371632

Award Identifier / Grant number: 30171070

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported by the National Natural Science Foundation of China (30772595, 30371632, 30171070).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Agilent Technologies. CrysAlisPro (version 1.171.37.35); Agilent Technologies UK Ltd: Yarnton, England, 2014.Search in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Farrugia, L. J. WinGX and ORTEP for windows: an update. J. Appl. Crystallogr. 2012, 45, 849–854; https://doi.org/10.1107/s0021889812029111.Search in Google Scholar

5. Zheng, X. H., Li, W., Lan, Z. P., Yang, X., Li, L. J., Yuan, Y. H., Zhu, X., Cen, X. G., Zhang, X. Y., Yu, Y. Antitumour effects of tetrazanbigen against human hepatocellular carcinoma qgy-7701 through inducing lipid accumulation in vitro and in vivo. J. Pharm. Pharmacol. 2015, 67, 1593–1602; https://doi.org/10.1111/jphp.12467.Search in Google Scholar

6. Xiang, C., Gan, Y. J., Yu, Y., Zhang, Y. Synthesis and evaluation of new sterol derivatives as potential antitumor agents. RSC Adv. 2018, 8, 26528–26537.10.1039/C8RA04152KSearch in Google Scholar

7. Hu, X. L., Wan, C. M., Gan, Z. J., Liu, R. X., Chen, Y. J., Wang, J., Gan, L. L., Chen, Y. H., Li, Y. B., He, B. C., Yu, Y. TNBG-5602, a novel derivative of quinoxaline, inhibits liver cancer growth via upregulating peroxisome proliferator-activated receptor γ in vitro and in vivo. J. Pharm. Pharmacol. 2019, 71, 1684–1694.https://doi.org/10.1111/jphp.13159.Search in Google Scholar

8. Gan, L. L., Gan, Z. J., Dan, Y. R., Li, Y. W., Zhang, P. M., Chen, S. W., Ye, Z. J., Pan, T., Wan, C. M., Hu, X. L., Yu, Y. Tetrazanbigen derivatives as peroxisome proliferator-activated receptor gamma (PPARγ) partial agonists: design, synthesis, structure–activity relationship, and anticancer activities. J. Med. Chem. 2021, 64, 1018–1036; https://doi.org/10.1021/acs.jmedchem.0c01512.Search in Google Scholar

9. Xi, M. Y., Jia, J. M., Sun, H. P., Sun, Z. Y., Jiang, J. W., Wang, Y. J., Zhang, M. Y., Zhu, J. F., Xu, L. L., Jiang, Z. Y., Xue, X., Ye, M., Yang, X., Gao, Y., Tao, L., Guo, X. K., Xu, X. L., Zhang, X. J., Guo, Q. L., Hu, R., You, Q. D. 3-Aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a] isoquinolin-4(11bH) ones as potent Nrf2/ARE inducers in human cancer cells and AOM-DSS treated mice. J. Med. Chem. 2013, 56, 7925–7938; https://doi.org/10.1021/jm400944k.Search in Google Scholar

10. Zhang, P. M., Li, Y. W., Zhou, J., Chen, Y. J., Gan, Z. J., Yu, Y. A one-pot facile synthesis of 2,3-dihydroxyquinoxaline and 2,3-dichloroquinoxaline derivatives using silica gel as an efficient catalyst. J. Heterocycl. Chem. 2018, 55, 1809–1814; https://doi.org/10.1002/jhet.3224.Search in Google Scholar

11. Makoto, N. M., Isaac, N. P., Marilyn, M. O., Tadeusz, F. M. Simplified cyclic analogues of bastadin-5. Structure-activity relationships for modulation of the RyR1/FKBP12 Ca2+ channel complex. J. Med. Chem. 2006, 49, 4497–4511.10.1021/jm050708uSearch in Google Scholar PubMed PubMed Central

12. Dan, Y. R., Gan, L. L., Yu, Y. Crystal structure of 2-methoxy-4b,5, 14,15-tetrahydro-6H-isoquinolino[2′,1′:1,6] pyrazino[2,3-b] quinoxaline, C19H18N4O. Z. Kristallogr. N. Cryst. Struct. 2021, 236, 595–597; https://doi.org/10.1515/ncrs-2021-0008.Search in Google Scholar

13. Chen, Y. H., Dan, Y. R., Gan, L. L., Yu, Y. Crystal structure of 3-fluoro-9-methoxy-4b,5,14,15-tetrahydro-6H-isoquinolino [2′,1′:1,6] pyrazino[2,3-b]quinoxaline, C19H17FN4O. Z. Kristallogr. N. Cryst. Struct. 2020, 235, 401–402; https://doi.org/10.1515/ncrs-2019-0708.Search in Google Scholar
Received: 2022-01-13
Accepted: 2022-02-07
Published Online: 2022-03-07
Published in Print: 2022-06-27

© 2022 Qiu Yu Zhang and Yu Yu, published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of (E)-(4-imidazol-1-yl-phenyl)-(2-methoxy-benzylidene)-amine monohydrate, C17H17N3O2
  4. Crystal structure of 6-methyl-3-(pyrrolidine-1-carbonyl)-2H-chromen-2-one, C15H15N1O3
  5. Crystal structure of 4-methyl-4-nitropentanoic acid, C6H11NO4
  6. The crystal structure of (E)-3-(furan-2-yl)acrylonitrile, C7H5NO
  7. Crystal structure of 3-(difluoromethyl)-1-methyl-N-(4,11,11-trimethyl-1,2,3,4-tetrahydro-1,4-methanoacridin-9-yl)-1H-pyrazole-4-carboxamide monohydrate, C23H26F2N4O3
  8. Crystal structure of 2-(4-bromobenzyloxy)-6-chloropyridine, C12H9BrClNO
  9. Crystal structure of N-(4-bromo-2,6-dichloro-phenyl)pyrazin-2-amine, C10H6BrCl2N3
  10. Crystal structure of (E)-1-(2–nitrophenyl)-3-phenylprop-2-en-1-one, C15H11NO3
  11. The crystal structure of (E)-3-chloro-2-(2-(4-fluorobenzylidene)hydrazinyl)pyridine, C12H9ClFN3
  12. Crystal structure of (E)-amino(2-(thiazol-2-ylmethylene)hydrazineyl)methaniminium nitrate, C10H16N12O6S2
  13. Crystal structure of 9-methoxy-2,3,4,4a,5,6-hexahydro-1H-pyrido [1′,2′:1,6]pyrazino[2,3-b]quinoxaline, C15H18N4O
  14. The crystal structure bis(dimethylsulfoxide-κ1O)-dipyridine-κ1 N-bis(m2-(Z)-3-methyl-2-oxido-N-((Z)-oxido(phenyl)methylene)benzohydrazonato-κ5)trinickel(II) - dimethylsulfoxide (1/2), C48H56N6Ni3O10S4
  15. Crystal structure of bis(bis(triphenylphosphine)iminium) tetradecacarbonyltetratelluridopentaferrate(2-), (PPN)2[Fe5Te4(CO)14]
  16. Crystal structure of 4-Hydroxy-3-(naphthalen-2-ylthio)pent-3-en-2-one, C15H14O2S
  17. The crystal structure of [(1,10-phenanthroline-κ2 N,N)-bis(6-phenylpyridine-2-carboxylate-κ2 N,O)nickel(II)] monohydrate, C36H26N4O5Ni
  18. Crystal structure of 3,3′-(pyridine-2,6-diylbis(methylene))bis(1-propyl-1H-imidazol-3-ium) ditetrafluoroborate, C19H27B2F8N5
  19. The crystal structure of (E)-1-(4-aminophenyl)-3-(p-tolyl)prop-2-en-1-one, C16H15NO
  20. The crystal structure of poly[(μ2-terephthalato-κ4O,O′: O″,O‴)-(μ4-terephthalato-κ4O:O′:O″:O‴)-{μ4-(1,2,4,5-tetrakis(1,2,4-triazol-1-ylmethyl)-benzene-κ4O:O′:O″,O‴)}dicadmium(II)] – water – acetronitrile (1/2/2), C38H36N14O10Cd2
  21. The crystal structure of diaqua-bis(6-phenylpyridine-2-carboxylato-κ2 N,O)cobalt(II)–water–N,N-dimethylformamide(1/2/1), C27H31N3O9Co
  22. The co-crystal structure of 4-hydroxy-3-methoxybenzoic acid – 4,4′-bipyridine, C8H8O4·C10H8N2
  23. Crystal structure of catena-poly[(μ2-1,1′-(biphenyl-4,4′-diyl)bis(1H-imidazol)-κ2N:N′)-bis(4-bromobenzoate-κ1O)cobalt(II)], C32H22Br2CoN4O4
  24. Crystal structure of (E)-5-propyl-4-((pyridin-2-ylmethylene)amino)-2,4-dihydro-3H-1,2,4-triazole-3-thione – methanol (1/1), C11H13N5S
  25. The crystal structure of (Z)-4-bromo-6-(((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)methylene)cyclohexa-2,4-dien-1-one monohydrate, C11H16BrNO5
  26. Crystal structure of bis(tetrapropylammonium) nonaselenidotetrastannate(IV), (Pr4N)2[Sn4Se9]
  27. Crystal structure of 2,6-di-tert-butyl-4-(4-chlorobenzylidene)cyclohexa-2,5-dien-1-one, C21H25ClO
  28. Crystal structure of (2,2′-((naphthalen-1-ylmethyl)azanediyl)diacetato-κ3 N,O,O′)-(1,10-phenanthroline-κ2 N,N′)-copper(II) trihydrate, CuC27H27N3O7
  29. The crystal structure of tetrakis(6-phenylpyridine-2-carboxylato-κ2N,O)-bis(1H-pyrazol-3-ylamine-κ2 N:N)dicobalt(II) dihydrate, C27H23N5O5Co
  30. The crystal structure of bis((E)-2-((tert-butylimino)methyl)-4-chlorophenolato-κ2N,O)zinc(II), C22H26Cl2N2O2Zn
  31. The crystal structure of poly[diaqua-(μ3-5-nitrobenzene-1,2,3-tricarboxylato-κ3O:O′:O′)-(μ2-4,4′-dipyridylamine-κ2N:N′)copper(II)], C38H30Cu3N8O20
  32. The crystal structure of (E)-1-ferrocenyl-3-(naphthalen-1-yl)prop-2-en-1-one, C23H18FeO
  33. The crystal structure of (E)-1-ferrocenyl-3-(4-isopropylphenyl)prop-2-en-1-one, C22H22FeO
  34. Crystal structure of 6-hydroxy-2,2-dimethyl-4Hbenzo[d][1,3]dioxin-4-one, C10H10O4
  35. The crystal structure of (2E,4E)-1-ferrocenyl-5-phenylpenta-2,4-dien-1-one, C21H18FeO
  36. Crystal structure of alaninato-κ2N,O-bis(hydroxylamido-κ2N,O)-oxido-vanadium(V), C3H10N3O5V
  37. Crystal structure of catena-poly[aqua-bis[μ2-6-(1H-imidazol-1-yl)nicotinato-κ2 N,O]copper(II)], C18H14N6O5Cu
  38. Crystal structure of diethyl 4,6-diphenyl-1,9-di-p-tolylhexahydro-3H-2,7,3,5-(epimethanetriyliminomethanetriyl)cyclopenta[b]pyridine-3,5(2H)-dicarboxylate, C42H42N2O4
  39. The crystal structure of cobalt cadmium bis(hydrogenphosphate) bis(phosphate(V)) tetrahydrate, H10O20P4Co3.14Cd1.86
  40. Crystal structure of dimethyl 1,4,6,9-tetraphenylhexahydro-3H-2,7,3,5-(epimethanetriyliminomethanetriyl)cyclopenta[b]pyridine-3,7(2H)-dicarboxylate, C38H34N2O4
  41. Crystal structure of (Z)-4-(furan-2-yl((4-iodophenyl)amino)methylene)-5-methyl-2(p-tolyl)-2,4-dihydro-3H-pyrazol-3-one, C21H16I N3O2
  42. Crystal structure of (E)-1-(4-(3,5-dimethoxystyryl)phenyl)-7-ethylheptanedioate, C25H30O6
  43. Crystal structure of 6-bromo-2-(4-chlorophenyl)chroman-4-one (6-bromo-4′-chloroflavanone), C15H10BrClO2
  44. The crystal structure of 2-(benzhydryloxy)-3-nitropyridine, C18H14N2O3
  45. The crystal structure of 1,3(4,1)-dipyridin-1-iuma-2(1,8)-diethynylanthracena-5(1,3)-benzenacyclohexaphane-11,31-diium bis(hexafluoridophosphate), C36H24F12N2P2
  46. Crystal structure of 3,6-di-tert-butyl-1-iodo-9-methyl-8-(pyren-1-ylethynyl)-9H-carbazole, C39H34IN
  47. The cocrystal 2-(dimethylammonio)-5-nitrobenzoate – 2-(dimethylamino)-5-nitrobenzoic acid, C9H10N2O4
  48. Crystal structure of 5-nitroquinazolin-4(3H)-one, C8H5N3O3
https://doi.org/10.1515/ncrs-2022-0012
Creative Commons
BY 4.0

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of (E)-(4-imidazol-1-yl-phenyl)-(2-methoxy-benzylidene)-amine monohydrate, C17H17N3O2
  4. Crystal structure of 6-methyl-3-(pyrrolidine-1-carbonyl)-2H-chromen-2-one, C15H15N1O3
  5. Crystal structure of 4-methyl-4-nitropentanoic acid, C6H11NO4
  6. The crystal structure of (E)-3-(furan-2-yl)acrylonitrile, C7H5NO
  7. Crystal structure of 3-(difluoromethyl)-1-methyl-N-(4,11,11-trimethyl-1,2,3,4-tetrahydro-1,4-methanoacridin-9-yl)-1H-pyrazole-4-carboxamide monohydrate, C23H26F2N4O3
  8. Crystal structure of 2-(4-bromobenzyloxy)-6-chloropyridine, C12H9BrClNO
  9. Crystal structure of N-(4-bromo-2,6-dichloro-phenyl)pyrazin-2-amine, C10H6BrCl2N3
  10. Crystal structure of (E)-1-(2–nitrophenyl)-3-phenylprop-2-en-1-one, C15H11NO3
  11. The crystal structure of (E)-3-chloro-2-(2-(4-fluorobenzylidene)hydrazinyl)pyridine, C12H9ClFN3
  12. Crystal structure of (E)-amino(2-(thiazol-2-ylmethylene)hydrazineyl)methaniminium nitrate, C10H16N12O6S2
  13. Crystal structure of 9-methoxy-2,3,4,4a,5,6-hexahydro-1H-pyrido [1′,2′:1,6]pyrazino[2,3-b]quinoxaline, C15H18N4O
  14. The crystal structure bis(dimethylsulfoxide-κ1O)-dipyridine-κ1 N-bis(m2-(Z)-3-methyl-2-oxido-N-((Z)-oxido(phenyl)methylene)benzohydrazonato-κ5)trinickel(II) - dimethylsulfoxide (1/2), C48H56N6Ni3O10S4
  15. Crystal structure of bis(bis(triphenylphosphine)iminium) tetradecacarbonyltetratelluridopentaferrate(2-), (PPN)2[Fe5Te4(CO)14]
  16. Crystal structure of 4-Hydroxy-3-(naphthalen-2-ylthio)pent-3-en-2-one, C15H14O2S
  17. The crystal structure of [(1,10-phenanthroline-κ2 N,N)-bis(6-phenylpyridine-2-carboxylate-κ2 N,O)nickel(II)] monohydrate, C36H26N4O5Ni
  18. Crystal structure of 3,3′-(pyridine-2,6-diylbis(methylene))bis(1-propyl-1H-imidazol-3-ium) ditetrafluoroborate, C19H27B2F8N5
  19. The crystal structure of (E)-1-(4-aminophenyl)-3-(p-tolyl)prop-2-en-1-one, C16H15NO
  20. The crystal structure of poly[(μ2-terephthalato-κ4O,O′: O″,O‴)-(μ4-terephthalato-κ4O:O′:O″:O‴)-{μ4-(1,2,4,5-tetrakis(1,2,4-triazol-1-ylmethyl)-benzene-κ4O:O′:O″,O‴)}dicadmium(II)] – water – acetronitrile (1/2/2), C38H36N14O10Cd2
  21. The crystal structure of diaqua-bis(6-phenylpyridine-2-carboxylato-κ2 N,O)cobalt(II)–water–N,N-dimethylformamide(1/2/1), C27H31N3O9Co
  22. The co-crystal structure of 4-hydroxy-3-methoxybenzoic acid – 4,4′-bipyridine, C8H8O4·C10H8N2
  23. Crystal structure of catena-poly[(μ2-1,1′-(biphenyl-4,4′-diyl)bis(1H-imidazol)-κ2N:N′)-bis(4-bromobenzoate-κ1O)cobalt(II)], C32H22Br2CoN4O4
  24. Crystal structure of (E)-5-propyl-4-((pyridin-2-ylmethylene)amino)-2,4-dihydro-3H-1,2,4-triazole-3-thione – methanol (1/1), C11H13N5S
  25. The crystal structure of (Z)-4-bromo-6-(((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)methylene)cyclohexa-2,4-dien-1-one monohydrate, C11H16BrNO5
  26. Crystal structure of bis(tetrapropylammonium) nonaselenidotetrastannate(IV), (Pr4N)2[Sn4Se9]
  27. Crystal structure of 2,6-di-tert-butyl-4-(4-chlorobenzylidene)cyclohexa-2,5-dien-1-one, C21H25ClO
  28. Crystal structure of (2,2′-((naphthalen-1-ylmethyl)azanediyl)diacetato-κ3 N,O,O′)-(1,10-phenanthroline-κ2 N,N′)-copper(II) trihydrate, CuC27H27N3O7
  29. The crystal structure of tetrakis(6-phenylpyridine-2-carboxylato-κ2N,O)-bis(1H-pyrazol-3-ylamine-κ2 N:N)dicobalt(II) dihydrate, C27H23N5O5Co
  30. The crystal structure of bis((E)-2-((tert-butylimino)methyl)-4-chlorophenolato-κ2N,O)zinc(II), C22H26Cl2N2O2Zn
  31. The crystal structure of poly[diaqua-(μ3-5-nitrobenzene-1,2,3-tricarboxylato-κ3O:O′:O′)-(μ2-4,4′-dipyridylamine-κ2N:N′)copper(II)], C38H30Cu3N8O20
  32. The crystal structure of (E)-1-ferrocenyl-3-(naphthalen-1-yl)prop-2-en-1-one, C23H18FeO
  33. The crystal structure of (E)-1-ferrocenyl-3-(4-isopropylphenyl)prop-2-en-1-one, C22H22FeO
  34. Crystal structure of 6-hydroxy-2,2-dimethyl-4Hbenzo[d][1,3]dioxin-4-one, C10H10O4
  35. The crystal structure of (2E,4E)-1-ferrocenyl-5-phenylpenta-2,4-dien-1-one, C21H18FeO
  36. Crystal structure of alaninato-κ2N,O-bis(hydroxylamido-κ2N,O)-oxido-vanadium(V), C3H10N3O5V
  37. Crystal structure of catena-poly[aqua-bis[μ2-6-(1H-imidazol-1-yl)nicotinato-κ2 N,O]copper(II)], C18H14N6O5Cu
  38. Crystal structure of diethyl 4,6-diphenyl-1,9-di-p-tolylhexahydro-3H-2,7,3,5-(epimethanetriyliminomethanetriyl)cyclopenta[b]pyridine-3,5(2H)-dicarboxylate, C42H42N2O4
  39. The crystal structure of cobalt cadmium bis(hydrogenphosphate) bis(phosphate(V)) tetrahydrate, H10O20P4Co3.14Cd1.86
  40. Crystal structure of dimethyl 1,4,6,9-tetraphenylhexahydro-3H-2,7,3,5-(epimethanetriyliminomethanetriyl)cyclopenta[b]pyridine-3,7(2H)-dicarboxylate, C38H34N2O4
  41. Crystal structure of (Z)-4-(furan-2-yl((4-iodophenyl)amino)methylene)-5-methyl-2(p-tolyl)-2,4-dihydro-3H-pyrazol-3-one, C21H16I N3O2
  42. Crystal structure of (E)-1-(4-(3,5-dimethoxystyryl)phenyl)-7-ethylheptanedioate, C25H30O6
  43. Crystal structure of 6-bromo-2-(4-chlorophenyl)chroman-4-one (6-bromo-4′-chloroflavanone), C15H10BrClO2
  44. The crystal structure of 2-(benzhydryloxy)-3-nitropyridine, C18H14N2O3
  45. The crystal structure of 1,3(4,1)-dipyridin-1-iuma-2(1,8)-diethynylanthracena-5(1,3)-benzenacyclohexaphane-11,31-diium bis(hexafluoridophosphate), C36H24F12N2P2
  46. Crystal structure of 3,6-di-tert-butyl-1-iodo-9-methyl-8-(pyren-1-ylethynyl)-9H-carbazole, C39H34IN
  47. The cocrystal 2-(dimethylammonio)-5-nitrobenzoate – 2-(dimethylamino)-5-nitrobenzoic acid, C9H10N2O4
  48. Crystal structure of 5-nitroquinazolin-4(3H)-one, C8H5N3O3
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 8.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2022-0012/html
Scroll to top button